

PRESS RELEASE

Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York

(Oxfordshire, UK and Conshohocken, Pennsylvania and Rockville, Maryland, US, 30 May 2019) Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, today announces that Bahija Jallal, Chief Executive Officer, and David Berman, Head of Research and Development, will be presenting at the Jefferies 2019 Global Healthcare Conference in New York on Friday 7 June at 2:30pm ET.

For meeting requests, please contact Julian Hirst at Julian.Hirst@immunocore.com.

- Ends -

About Immunocore

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company's primary therapeutic focus is oncology and it also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and the lead programme, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.

For more information, please contact:

Immunocore

Louise Conlon, External Affairs and Brand Communications Manager

T: +44 (0) 1235 438600

E: info@immunocore.com

Follow on Twitter: [@Immunocore](https://twitter.com/Immunocore)

Consilium Strategic Communications (corporate and financial)

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Melissa Gardiner

T: +44 (0)203 709 5700

E: Immunocore@consilium-comms.com